U.S. FDA Placed a Clinical Hold on BMN 307 Phearless Phase 1/2 Gene Therapy Study in Adults with PKU Based on Interim Pre-clinical Study Findings

Contacts: |
|
Investors? |
Media |
Traci McCarty? |
Debra Charlesworth |
BioMarin Pharmaceutical Inc.? |
BioMarin Pharmaceutical Inc. |
(415) 455-7558 |
(415) 455-7451 |